Pharma in Focus After Hours: Kythera (NASDAQ:KYTH), La Jolla Pharmaceutical (NASDAQ:LJPC), Medifast (NYSE:MED)
Kythera (NASDAQ:KYTH) and Bayer ADR (OTCMRKTS:BAYRY) announced that Kythera acquired all rights outside of the U.S. and Canada to ATX-101, a proprietary formulation of a purified synthetic version of deoxycholic acid currently in late-stage development for the reduction of submental fat (double chin). In 2010, KYTHERA (NASDAQ:KYTH) licensed the commercial rights to ATX-101 outside of…
